In a research paper authored by OmegaQuant’s Dr. Kristina Harris Jackson, there was a focus on two main studies. One looked at blood levels of women who had a full term pregnancy or those who had early preterm birth (giving birth before 34 weeks). In this study, they found that those who had higher omega-3s in their blood had a lower risk of being an early preterm birth case. At around 5% DHA in the blood you start to see that risk decrease and continue to lessen with an increase in blood DHA level. On the other hand, below 5% there is an extremely steep risk curve for early preterm birth. For example, those with a 3% DHA level were 10x more likely to have a preterm birth than those above 5%. So being 5% and above is the main goal. Getting women who are low and above 5% could help them avoid premature birth. Another important study Dr. Jackson and her colleagues looked at in establishing the rationale for the Prenatal DHA Test was a meta-analysis of 70 studies in pregnancy where one group was given a fish oil during pregnancy and the other a placebo. When all of these studies were pooled together, they found a very strong effect on preterm and early preterm birth risk. Those taking fish oil had a reduced risk of 11% and 42% for preterm and early preterm birth, respectively. They also found that taking fish oil — even at high doses — was safe for mom and baby during pregnancy. Both of these studies together supported the need for having a simple, safe blood test for measuring DHA. This way women could know what that level is and adjust safely as needed to lower their risk for preterm birth. 

Here is a helpful blog post.

Here is a helpful video.

These statements have not been evaluated by the Food and Drug Administration. This test is not intended to diagnose, treat, cure, prevent or mitigate any disease. This site does not offer medical advice, and nothing contained herein is intended to establish a doctor/patient relationship. OmegaQuant, LLC is regulated under the Clinical Laboratory improvement Amendments of 1988 (CLIA) and is qualified to perform high complexity clinical testing. The performance characteristics of this test were determined by OmegaQuant, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration.